Takahashi Yoshiaki

タカハシヨシアキ | Takahashi Yoshiaki

Affiliation and department：
Job title： Laboratory Head, Laboratory of Medicinal Chemistry
Homepage URL (2)： http://www.bikaken.or.jp , http://www.bikaken.or.jp

Research field (3)： Pharmaceuticals - chemistry and drug development , Biochemistry , Molecular biochemistry

Research keywords (6)：糖質化学 , Medicinal Chemistry , 生物有機化学 , 抗生物質 , Bioorganic Chemistry , Antibiotics

Research theme for competitive and other funds (5)：

2019 - 2022 抗生物質の再評価と既承認薬の再配置による新規抗菌薬の創製
2016 - 2019 超多剤耐性グラム陰性菌に有効な新規抗菌化合物の探索と創製
2001 - Synthetic Study on Protease Inhibitor
1999 - Synthetic Study on Cyclitols
Synthetic Study on Antibiotics

Papers (29)：

Yoshimasa Ishizaki, Yoshiaki Takahashi, Tomoyuki Kimura, Michitaka Inoue, Chigusa Hayashi, Masayuki Igarashi. Synthesis and biological activity of analogs of CPZEN-45, a novel antituberculosis drug. The Journal of Antibiotics. 2019. 72. 12. 970-980
五十嵐雅之, 高橋良昭. 天然物からの次世代新規抗生物質の探索. 日本化学療法学会雑誌. 2019. 67. 3. 308-323
Yoshiaki Takahashi, Eijiro Umemura, Yoshihiko Kobayashi, Shoichi Murakami, Toru Nawa, Akihiro Morinaka, Toshiaki Miyake, Masakatsu Shibasaki. Discovery of 2-hydroxyarbekacin, a new aminoglycoside antibiotic with reduced nephrotoxicity. Journal of Antibiotics. 2018. 71. 2. 345-347
Hideki Hashizume, Yoshiaki Takahashi, Tohru Masuda, Shun-ichi Ohba. In vivo efficacy of β-lactam/tripropeptin C in a mouse septicemia model and the mechanism of. The Journal of Antibiotics. 2018. 71. 1. 79-85
Masayuki Igarashi, Yoshimasa Ishizaki, Yoshiaki. New antituberculous drugs derived from natural products: current perspectives and issues in. The Journal of Antibiotics. 2018. 71. 1. 15-25

ｍore...

MISC (6)：

Novel Semisynthetic Antibiotics from Caprazamycins(Part2):Caprazol Derivatives and Their Anti-Mycobacterium tuberculosis Activity. "jointly worked". The 43rd INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS&CHEMOTHERAPY,. 2003. F-2141
Novel Semisynthetic Antibiotics from Caprazamycins(Part1):Caprazene Derivatives and Their Anti-Mycobacterium tuberculosis Activity. "jointly worked". The 43rd INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS&CHEMOTHERAPY,. 2003. F-2140
Novel Semisynthetic Antibiotics from Caprazamycins(Part2):Caprazol Derivatives and Their Anti-Mycobacterium tuberculosis Activity. "jointly worked". The 43rd INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS&CHEMOTHERAPY,. 2003. F-2141
Novel Semisynthetic Antibiotics from Caprazamycins(Part1):Caprazene Derivatives and Their Anti-Mycobacterium tuberculosis Activity. "jointly worked". The 43rd INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS&CHEMOTHERAPY,. 2003. F-2140
"Synthesis of a Fluorinated Derivative of Coformycin, a Potent Inhibitor of Adenosine Deaminase". 1996. 645

ｍore...

Patents (4)：

多剤耐性菌に有効な新規アミノグリコシド抗生物質
多剤耐性菌に有効な新規アミノグリコシド抗生物質
2'-Deoxy-2'-fluorocoformycin and stereoisomers thereof
3'-Fluoro-3'-Deoxykanamycin A and the Production Thereof

Books (2)：

薬剤耐性と創薬研究-アミノグリコシド系抗生物質を中心としてー
オベリスク(Obe-lisk) 2017
新しい抗結核薬の開発状況
日本臨牀 2011

Lectures and oral presentations (53)：

多剤耐性グラム陰性菌に有効なアプラマイシン誘導体の創薬研究
(第35回メディシナルケミストリーシンポジウム 2019)
クライオ電顕を用いた大腸菌リボソームへの新規アミノ配糖体結合様式の解明
(生理研研究会「クライオ電子顕微鏡によるタンパク質の高分解能単粒子構造解析」 2019)
新規抗結核薬CPZEN-45の創製と開発
(日本細菌学会関東支部インターラボセミナー 2019)
超多剤耐性グラム陰性菌に有効な新規抗菌薬の開発
(日本細菌学会関東支部インターラボセミナー 2019)
既知の耐性機構を回避する新規アミノ配糖体系抗菌薬の探索と創製
(第48回薬剤耐性菌研究会 2019)

ｍore...

Education (1)：

- 1983 Keio University

Professional career (2)：

Doctor(Engineering) (Keio University)
Master(Engineering) (Keio University)

Work history (10)：

2019/05 - 現在 (公益財団法人)日本感染症医薬品協会評議員
2017/06 - 現在 Microbial Chemistry Research Foundation Director
2015/04 - 現在 Keio University Faculty of Science and Technology, Department of Applied Chemistry
2015/04 - 現在 (公益財団法人)微生物化学研究会微生物化学研究所創薬化学研究部部長
2011/04 - 2015/03 (公益財団法人)微生物化学研究会微生物化学研究所日吉支所主席研究員

Show all

Committee career (1)：

2016/06 - 現在薬事・食品衛生審議会専門委員

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page